Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02395471 · ClinicalTrials.gov registry record · NA
Cytosponge Adequacy Study Evaluation II
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 191
- Enrollment target
NCT02395471: Completed NA study, sponsored by Medtronic - MITG.
NCT02395471 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 191 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02395471, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 191 participants
- Enrollment target
Study Summary
This study will assess the Minimally Invasive Esophageal Cytology Collection System in Patients with Barrett's Esophagus or GERD Symptoms.
Primary Outcome
The first primary objective of the study was to assess the acceptability of a novel, minimally invasive esophageal mucosal sampling technique, the Cytosponge™, in subjects undergoing surveillance of BE who have had at least a C1 or M3 segment confirmed, and 2) in subjects with GERD undergoing screening for BE. This includes measures of acceptability as demonstrated on the Impact of Event Scale, a Visual Analog Scale for Pain, and the subject's willingness to undergo repeat Cytosponge™ administra
Interventions
- DEVICE Cytosponge™ Cell Collection Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-06-01 |
| Phase | NA |
What the finished NCT02395471 record still lists
NCT02395471 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Cytosponge™ Cell Collection Device is the first listed.
NCT02395471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02395471 about?
NCT02395471 is a clinical study titled "Cytosponge Adequacy Study Evaluation II". This study will assess the Minimally Invasive Esophageal Cytology Collection System in Patients with Barrett's Esophagus or GERD Symptoms.
What is the current status of trial NCT02395471?
This trial is currently completed. It is a NA study. The enrollment target is 191 participants. The study started on 2015-08. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT02395471?
The interventions under investigation include: Cytosponge™ Cell Collection Device (DEVICE).
Who is sponsoring clinical trial NCT02395471?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02395471's enrollment target sits among peer trials
191 574th of 2000 higher than 1,427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia